U.S. markets close in 1 hour 35 minutes
  • S&P 500

    4,134.72
    -38.70 (-0.93%)
     
  • Dow 30

    33,794.22
    -343.09 (-1.01%)
     
  • Nasdaq

    13,815.90
    -134.32 (-0.96%)
     
  • Russell 2000

    2,232.70
    -6.92 (-0.31%)
     
  • Crude Oil

    61.17
    -0.18 (-0.29%)
     
  • Gold

    1,780.20
    -12.90 (-0.72%)
     
  • Silver

    26.07
    -0.50 (-1.88%)
     
  • EUR/USD

    1.2003
    -0.0036 (-0.30%)
     
  • 10-Yr Bond

    1.5520
    -0.0120 (-0.77%)
     
  • GBP/USD

    1.3828
    -0.0104 (-0.75%)
     
  • USD/JPY

    108.1110
    +0.0680 (+0.06%)
     
  • BTC-USD

    53,096.18
    -2,643.49 (-4.74%)
     
  • CMC Crypto 200

    1,242.34
    -0.71 (-0.06%)
     
  • FTSE 100

    6,938.24
    +42.95 (+0.62%)
     
  • Nikkei 225

    29,188.17
    +679.62 (+2.38%)
     

Biocept Inks Research Pact With Protean BioDiagnostics For Target Selector Kit Advantages In Lung Cancer

  • Oops!
    Something went wrong.
    Please try again later.
Vandana Singh
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Biocept Inc (NASDAQ: BIOCwill collaborate with Protean BioDiagnostics Inc to research Biocept's Target Selector molecular assay's ability to determine EGFR status in non-small cell lung cancer (NSCLC) patients.

  • The research will be conducted in an independent pathology laboratory setting.

  • Protean BioDiagnostics also expects to validate a laboratory-developed test's analytical performance based on Biocept's EGFR assay test kit.

  • Biocept's molecular assay kit, available for research-use-only and with CE-IVD mark, is used to analyze both formalin-fixed paraffin-embedded tissue samples and circulating tumor DNA from biological fluids.

  • The molecular assays have been validated to detect frequent oncogenic mutations EGFR, KRAS, and BRAF, which are the most frequently evaluated biomarkers for lung cancer and melanoma.

  • Price Action: BIOC stock is down 9.2% at $6.5 in market trading hours on the last check Tuesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.